Table S2.
Survival rate and median survival according to diabetic status before and after propensity matching
| Diabetic status | Unmatched (complete) dataset | Propensity score-matched (1:1) dataseta | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS | Median PFS (months) | CSS | Median CSS (months) | PFS | Median PFS (months) | CSS | Median CSS (months) | |||||||||
| 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | |||||
| Whole cohort | 76.9% | 65.7% | 59.3% | - | 91.0% | 76.2% | 72.8% | - | 73.5% | 61.1% | 52.8% | 70.03 | 87.8% | 67.8% | 61.1% | - |
| Diabetic group | 67.0% | 54.6% | 44.7% | 56.30 | 84.9% | 55.1% | 50.8% | - | 67.0% | 54.6% | 44.7% | 56.30 | 84.9% | 55.1% | 50.8% | - |
| Nondiabetic group | 79.3% | 68.4% | 62.2% | - | 92.5% | 81.0% | 77.8% | - | 79.7% | 67.4% | 59.2% | - | 90.7% | 76.9% | 71.6% | - |
Note: aPropensity score-matched (1:1, 109 pairs) analyses were performed with a small caliper of 0.1 for matching potential confounders including sex, age, stage, ECOG PS, extranodal site(s), Hans classification, symptoms and LDH level. p-values in bold < 0.05.
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PFS, progression-free survival; CSS, cancer-specific survival.